Nicotine and Cotinine Exposure from Electronic Cigarettes: A Population Approach

Clinical Pharmacokinetics

Volumn 54, Issue 6, 2015, Pages 615-626

  Vélez de Mendizábal, Nieves ^a,b   Jones, David R ^b   Jahn, Andy ^c   Bies, Robert R ^a,b   Brown, Joshua W ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Indiana Clinical and Translational Sciences Institute (CTSI)   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON DIOXIDE; COTININE; NICOTINE; CARBON MONOXIDE;

ADULT; AIRFLOW; ARTICLE; DRUG BLOOD LEVEL; ELECTRONIC CIGARETTE; FEMALE; HUMAN; INHALATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOKINETIC MODEL; POPULATION MODEL; PRIORITY JOURNAL; SIMULATION; VOLUME OF DISTRIBUTION; ADOLESCENT; BLOOD; BREATH ANALYSIS; EXPOSURE; MASS SPECTROMETRY; PROCEDURES; SMOKING; SOFTWARE; YOUNG ADULT;

ADOLESCENT; ADULT; BREATH TESTS; CARBON MONOXIDE; COTININE; ELECTRONIC CIGARETTES; FEMALE; HUMANS; INHALATION EXPOSURE; MALE; MASS SPECTROMETRY; NICOTINE; SMOKING; SOFTWARE; YOUNG ADULT;

EID: 84930081909     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0221-7     Document Type: Article

References (23)

1. Yamazaki H, Horiuchi K, Takano R, Nagano T, Shimizu M, Kitajima M, et al. Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling. Int J Environ Res Public Health. 2010;7:3406–21.
2. Teeguarden JG, Housand CJ, Smith JN, Hinderliter PM, Gunawan R, Timchalk CA. A multi-route model of nicotine–cotinine pharmacokinetics, pharmacodynamics and brain nicotinic acetylcholine receptor binding in humans. Regul Toxicol Pharmacol. 2013;65:12–28.
3. Robinson DE, Balter NJ, Schwartz SL. A physiologically based pharmacokinetic model for nicotine and cotinine in man. J Pharmacokinet Biopharm. 1992;20:591–609.
4. Etter JF, Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction. 2011;106:2017–28.
5. Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One. 2013;8:e66317.
6. Cheng T. Chemical evaluation of electronic cigarettes. Tob Control. 2014;23(Suppl 2):ii11–7.
7. Grana R, Benowitz N, Glantz SA. E-cigarettes: a scientific review. Circulation. 2014;129:1972–86.
8. Dawkins L, Corcoran O. Acute electronic cigarette use: nicotine delivery and subjective effects in regular users. Psychopharmacology (Berl). 2014;231:401–7.
9. Vansickel AR, Eissenberg T. Electronic cigarettes: effective nicotine delivery after acute administration. Nicotine Tob Res. 2013;15:267–70.
10. Flouris AD, Poulianiti KP, Chorti MS, Jamurtas AZ, Kouretas D, Owolabi EO, et al. Acute effects of electronic and tobacco cigarette smoking on complete blood count. Food Chem Toxicol. 2012;50:3600–3.
11. Schroeder MJ, Hoffman AC. Electronic cigarettes and nicotine clinical pharmacology. Tob Control. 2014;23(Suppl 2):ii30–5.
12. Hajek P, Goniewicz ML, Phillips A, Myers SK, West O, McRobbie H. Nicotine intake from electronic cigarettes on initial use and after 4 weeks of regular use. Nicotine Tob Res. Epub 2014 Aug 13.
13. Vansickel AR, Cobb CO, Weaver MF, Eissenberg TE. A clinical laboratory model for evaluating the acute effects of electronic “cigarettes”: nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol Biomarkers Prev. 2010;19:1945–53.
14. Eissenberg T. Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administration. Tob Control. 2010;19:87–8.
15. Middleton ET, Morice AH. Breath carbon monoxide as an indication of smoking habit. Chest. 2000;117:758–63.
16. Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57:79–115.
17. Armitage AK, Dollery CT, George CF, Houseman TH, Lewis PJ, Turner DM. Absorption and metabolism of nicotine from cigarettes. Br Med J. 1975;4:313–6.
18. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481–504.
19. Benowitz NL, Porchet H, Jacob P III. Nicotine dependence and tolerance in man: pharmacokinetic and pharmacodynamic investigations. Prog Brain Res. 1989;79:279–87.
20. Ludden TM, Beal SL, Sheiner LB. Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm. 1994;22:431–45.
21. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85–94.
22. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24:2187–97.
23. Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008;90:154–66.